Amneal Pharmaceuticals Inc (NYSE:AMRX) disclosed on Monday the receipt of US FDA approval for the generic version of the transdermal product Exelon Patch (Rivastigmine Transdermal System) in 4.6 mg/24 hours, 9.5 mg/24 hours and 13.3 mg/24 hours.
Following US FDA approval, the company said it intends to launch its Rivastigmine Transdermal System shortly.
For the 12 months ended November 2018, the US market annual sales for Rivastigmine Transdermal System is estimated at about USD225m, according to IQVIA,
Headquartered in Bridgewater, NJ, Amneal is a pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
MS Pharma enters strategic partnership with Hetero Group
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis